AbbVie enters world of pain in up to $715M deal with China’s Haisco
BioSpace
The licensing deal marks AbbVie's first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.
pharminent
April 13, 2026 (Last updated: April 13, 2026)
BioSpace
The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx.